MX365242B - El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim. - Google Patents

El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.

Info

Publication number
MX365242B
MX365242B MX2013013308A MX2013013308A MX365242B MX 365242 B MX365242 B MX 365242B MX 2013013308 A MX2013013308 A MX 2013013308A MX 2013013308 A MX2013013308 A MX 2013013308A MX 365242 B MX365242 B MX 365242B
Authority
MX
Mexico
Prior art keywords
cxcr4 antagonists
certain
disorders
compositions
treating
Prior art date
Application number
MX2013013308A
Other languages
English (en)
Spanish (es)
Other versions
MX2013013308A (es
Inventor
C Dale David
J Bridger Gary
J Hsu Frank
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2013013308A publication Critical patent/MX2013013308A/es
Publication of MX365242B publication Critical patent/MX365242B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2013013308A 2011-05-16 2012-05-15 El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim. MX365242B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486632P 2011-05-16 2011-05-16
PCT/US2012/037970 WO2012158707A1 (en) 2011-05-16 2012-05-15 Use of cxcr4 antagonists

Publications (2)

Publication Number Publication Date
MX2013013308A MX2013013308A (es) 2014-02-27
MX365242B true MX365242B (es) 2019-05-28

Family

ID=81755014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013308A MX365242B (es) 2011-05-16 2012-05-15 El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.

Country Status (11)

Country Link
US (2) US20150030561A1 (enExample)
EP (1) EP2709991B1 (enExample)
JP (1) JP2014513727A (enExample)
KR (3) KR20140045411A (enExample)
CN (1) CN103596935A (enExample)
BR (1) BR112013029482A2 (enExample)
ES (1) ES2831049T3 (enExample)
MX (1) MX365242B (enExample)
PL (1) PL2709991T3 (enExample)
RU (1) RU2638802C2 (enExample)
WO (1) WO2012158707A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006243776A1 (en) 2005-05-02 2006-11-09 Genzyme Corporation Gene therapy for neurometabolic disorders
US9419667B2 (en) 2013-04-16 2016-08-16 Skyworks Solutions, Inc. Apparatus and methods related to conformal coating implemented with surface mount devices
US9375406B2 (en) * 2014-09-30 2016-06-28 Taigen Biotechnology Co., Ltd. Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
US10610527B2 (en) * 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
IL320371A (en) * 2016-09-08 2025-06-01 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Gene therapy for patients with fanconi anemia
CN109988153B (zh) * 2017-12-29 2021-11-19 深圳夏浠湾医药科技有限公司 一种川芎嗪衍生物及其制备方法和应用
US12539316B2 (en) 2018-04-11 2026-02-03 Spacecraft Seven, Llc Compositions and methods for stem cell transplant
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
US20250276030A1 (en) * 2020-10-20 2025-09-04 Eom Pharmaceuticals Inc. Eom613 for treatment of covid-19
CN113662937B (zh) * 2021-10-09 2022-08-23 江苏省人民医院（南京医科大学第一附属医院） Plerixafor在上调EFTUD2表达和抑制HBV药物中的用途
CN116675708B (zh) * 2023-04-23 2026-06-23 华南师范大学 一类氧化响应的大环化合物、大环配合物及其应用
WO2025122961A1 (en) * 2023-12-08 2025-06-12 X4 Pharmaceuticals, Inc. Methods for treating neutropenia

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (enExample) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
DE69914463T2 (de) 1998-03-13 2004-11-11 The University Of British Columbia, Vancouver Therapeutische chemokine rezeptor antagonisten
WO2000009152A1 (en) 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
EP2308996A1 (en) 1998-03-30 2011-04-13 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
EP1244648B1 (en) 1999-12-17 2009-04-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds
CA2335109A1 (en) 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US20070160574A1 (en) 2000-04-12 2007-07-12 Ahmed Merzouk Design of CXC chemokine analogs for the treatment of human diseases
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
EP2324839B1 (en) 2000-06-05 2017-08-09 The Trustees of Columbia University in the City of New York Granulocyte-colony-stimulating-factor (g-csf) for use in the treatment of myocardial infarct
ES2320323T3 (es) 2000-09-29 2009-05-21 Anormed Inc. Procedimiento para la preparacion de poliamidas ciclicas con proteccion n-1 que contienen atomos de nitrogeno en forma de anillo n, y producto asi obtenido.
US20040157818A1 (en) 2001-05-24 2004-08-12 Mikiro Yanaka Cxcr4-antagonistic drugs composed of nitrogen-containing compound
CN102302493B (zh) 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
US7399776B2 (en) 2003-04-02 2008-07-15 Taigen Biotechnology Polyamine compounds for treating chemokine receptor mediated diseases
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
JP2008509928A (ja) 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
WO2006095542A1 (ja) 2005-03-04 2006-09-14 Kureha Corporation アミン系化合物を含む医薬組成物
US20080234294A1 (en) * 2005-08-18 2008-09-25 Novartis Ag Cxcr4 Binding Molecules
US20070043012A1 (en) 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
US20090221683A1 (en) * 2005-10-18 2009-09-03 Caritas St.Elizabeth Medical Center Of Boston, Inc Combination of CXCR4 Antagonist and Morphogen to Increase Angiogenesis
AU2006340074A1 (en) 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration
US8080659B2 (en) 2006-07-11 2011-12-20 Emory University CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders
JP2009545620A (ja) 2006-08-02 2009-12-24 ジェンザイム・コーポレーション 併用療法
MX2009001445A (es) 2006-08-07 2009-02-18 Genzyme Corp Terapia de combinacion.
MX2009008843A (es) 2007-02-28 2009-08-28 Polyphor Ltd Peptidomimeticos fijados a un patron.
CA2728124C (en) 2008-06-23 2014-12-02 Research In Motion Limited Method for delivering device and server capabilities
US20110245265A1 (en) 2008-08-29 2011-10-06 Genzyme Corporation Cxcr4 antagonists for kidney injury
JP2012516353A (ja) * 2009-01-30 2012-07-19 ジェンザイム・コーポレーション 血液系悪性腫瘍を治療するための方法及び組成物

Also Published As

Publication number Publication date
EP2709991B1 (en) 2020-09-02
KR20210094672A (ko) 2021-07-29
RU2013155601A (ru) 2015-06-27
KR20140045411A (ko) 2014-04-16
CN103596935A (zh) 2014-02-19
KR20200016407A (ko) 2020-02-14
US20150030561A1 (en) 2015-01-29
US20210161859A1 (en) 2021-06-03
EP2709991A1 (en) 2014-03-26
EP2709991A4 (en) 2014-10-01
MX2013013308A (es) 2014-02-27
WO2012158707A1 (en) 2012-11-22
JP2014513727A (ja) 2014-06-05
BR112013029482A2 (pt) 2016-08-09
PL2709991T3 (pl) 2021-04-06
RU2638802C2 (ru) 2017-12-15
ES2831049T3 (es) 2021-06-07

Similar Documents

Publication Publication Date Title
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
IL274134A (en) Methods of treating or preventing asthma by administering an IL-4R agonist
PL2709991T3 (pl) Zastosowanie antagonistów CXCR4 w leczeniu zespołu WHIM, mielokateksji, neutropenii i limfocytopenii
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
GB201017345D0 (en) Receptor antagonists
ZA201401117B (en) Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
IL253911A0 (en) Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
PL3107575T3 (pl) Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
PH12016500862B1 (en) Autotaxin inhibitor compounds
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
IL230705A0 (en) Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
MX2015008813A (es) Composiciones y metodos para contrarrestar la inhibicion del factor xa.
WO2014153495A3 (en) Novel stat3 inhibitors
MX2016007947A (es) Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con caracteristicas melancolicas.
MX351631B (es) Composiciones y metodos para reducir la incidencia de trastornos digestivos equinos.
EP2665488A2 (en) Methods and kits for assessing heparanase procoagulant activity, compositions comprising heparanase, and methods for the treatment of coagulation-related disorders
IL271284A (en) Methods for treating or preventing asthma by administering an antagonist to -il-r4
MX2012011207A (es) Combinaciones para el tratamiento de enfermedades obstructivas de las vias respiratorias.
IL227475A0 (en) Methods and kits for evaluating the pro-coagulation activity of heparanase' Preparations containing heparanase and methods for the treatment of disorders related to coagulation
IL247290A0 (en) Methods of treating or preventing asthma by adding an il-4r antagonist
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия

Legal Events

Date Code Title Description
FG Grant or registration